Inmunopatogenia of psoriasis. New progress

Authors

  • Luisa Elena Poleo Brito University Hospital of Caracas
  • Roseisela García University Hospital of Caracas

Keywords:

Psoriasis, genetics, autoimmunity, immunopathogenesis, immunotherapy

Abstract

Psoriasis is a chronic inflammatory disease of the skin. Its etiology involves several agents such as genetic susceptibility, immunological factors and multiple environmental elements, which can trigger and / or exacerbate the disease. In recent decades thorough research has been conducted on the pathogenesis of psoriasis, several T-cell subtypes that play a key role in the establishment of inflammation in skin lesions have been recognized. Genetic studies provide the basis for the construction of the disease model, demonstrating that dendritic cells, T lymphocytes and keratinocytes play a key role in the pathology of this entity, as well as a set of cytokines that drive psoriatic inflammation , such as include TNF , IL-22, IL-23 and IL-17, which promote the inflammatory response of keratinocytes, and the production of antimicrobial peptides, cytokines and chemokines, thus perpetuating the inflammatory response. At present, the development of several highly effective biological drugs has revolutionized the treatment of moderate to severe plaque psoriasis. These drugs are a reflection of a greater understanding of the pathogenesis of psoriasis, including the central importance of IL-23 and IL-17 and different signaling pathways. The objective of this work is to perform a critical review of the literature on psoriasis and the mechanisms involved in its imnunopathogenesis

Downloads

Download data is not yet available.

Author Biographies

Luisa Elena Poleo Brito, University Hospital of Caracas

Residente de segundo año de la Cátedra de Dermatología y Sifilografía. Hospital Universitario de Caracas, Caracas -Venezuela. 

Roseisela García, University Hospital of Caracas

Adjunto del Servicio de Dermatología y Sifilografía. Hospital Universitario de Caracas, Caracas -Venezuela. 

References

Diani M, Altomare G, and Reali E. T Helper Cell Subsets in Clinical

Manifestations of Psoriasis. J Immunol Res. 2016; 2016:1-7.

Sticherling M. Psoriasis and autoimmunity. Autoimmun Rev. 2016;

:1167-70.

Alexander H, Nestle FO. Pathogenesis and immunotherapy in

cutaneous psoriasis: what can rheumatologists learn?. Curr Opin

Rheumatol. 2017; 29(1):71-8.

Huang R, Li L, Wang M, Chen XM, Huang QC, Lu CJ. An

Exploration of the Role of MicroRNAs in Psoriasis. Medicine

(Baltimore). 2015; 94(45): e2030.

Mahil S, Capon F, Barker J. Update on psoriasis

immunopathogenesis and targeted immunotherapy. Semin

Immunopathol. 2016; 38(1):11-27.

González F, Páez E, Orta L, Rondón A, Olavarría F, Goihman M et

al. I Consenso Nacional De Psoriasis. Dermatol Venez. 2009; 47

(3): 37-56.

Puiga L, Juliàb A, Marsal S. Psoriasis: bases genéticas y

patogenéticas. Actas Dermosifiliogr. 2014; 105(6):535-45.

Marrakchi S, Guigue P, Renshaw B, Puel A, Pei XY, Fraitag S et al.

Interleukin-36-receptor antagonist deficiency and generalized

pustular psoriasis. N Engl J Med. 2011; 365: 620-8.

Jordan C, Cao L, Roberson E, Pierson KC, Yang CF, Joyce CE et al.

PSORS2 is due to mutations in CARD14. Am J Hum Genet. 2012;

:784-95.

Hawkes J, Nguyen G, Fujita M, Florell SR, Callis Duffin K, Krueger

GG et al. microRNAs in Psoriasis. J Invest Dermatol. 2016; 136

(2):365-71.

Hernández MC, García R. miARN en enfermedades inflamatorias

de la piel. Rev Digit Postgrado. 2016; 5(2): 30-6.

Lovendorf M, Skov L. miRNAs in inflammatory skin diseases and

their clinical implications. Expert Rev Clin Immunol. 2015;

(4):467-77.

Xiaoyun Y, Jingang A, Yunhui H, Li Z, Yan N, Fan W et al.

MicroRNA-194 regulates keratinocyte proliferation and

differentiation by targeting Grainyhead-like 2 in psoriasis. Pathol

Res Pract. 2016; 213 (2): 89-97.

Meisgen F, Xu N, Wei T, Janson PC, Obad S, Broom O et al. MiR21

is up-regulated inpsoriasis and suppresses T cell apoptosis. Exp

Dermatol. 2012; 21:312-4.

Lovendorf M, Zibert J, Gyldenlove M, Røpke MA, Skov L.

MicroRNA-223 and miR-143 are important systemic biomarkers for

disease activity in psoriasis. J Dermatol Sci. 2014; 75:133-9.

Sun Y, Zhang J, Zhai T, Li H, Li H, Huo R et al. CCN1 promotes IL1β

production in keratinocytes by activating p38 MAPK signaling in

psoriasis. Sci Rep. 2017;7:43310.

Owczarczyk A, Placek W. Interleukin-17 as a factor linking the

pathogenesis of psoriasis with metabolic disorders, Int J Dermatol.

; 56(3):260-8.

Peng C, Zhang S, Lei L, Zhang X, Jia X, Luo Z et al. Epidermal

CD147 expression plays a key role in IL-22-induced psoriatic

dermatitis. Sci Rep. 2017; 8(7):44172.

Wu P, Ma G, Zhu X, Gu T, Zhang J, Sun Y et al. Cyr61/CCN1 is

involved in the pathogenesis of psoriasis vulgaris via promoting IL8

production by keratinocytes in a JNK/NF-κB pathway. Clin

Immunol. 2017; 174:53-62.

Pinru W, Gang M, Ningli L. The profile of Cyr61 expression data

correlate to the skin inflammation in psoriasis, Data Brief. 2017;

: 487-91.

Campa M, Mansouri B, Warren R, Menter A. A Review of Biologic

Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe

Plaque Psoriasis. Dermatol Ther (Heidelb). 2016; 6(1):1-12.

Galluzzo M, D'adamio S, Bianchi L, Talamonti M. Tildrakizumab for

treating psoriasis. Expert Opin Biol Ther. 2017; 17:1-13.

Bruin G, Loesche C, Nyirady J, Sander O. Population

Pharmacokinetic Modeling of Secukinumab in Patients With

Moderate to Severe Psoriasis. J Clin Pharmacol. 2017. 57(7):876-

Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK-STAT

Signaling as a Target for Inflammatory and Autoimmune Diseases:

Current and Future Prospects. Drugs. 2017; 77(5):521-46.

How to Cite

Poleo Brito, L. E., & García, R. (2018). Inmunopatogenia of psoriasis. New progress. Revista Digital De Postgrado, 6(2). Retrieved from http://saber.ucv.ve/ojs/index.php/rev_dp/article/view/14914